$NAMS News

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses?

NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates

NewAmsterdam Pharma (NASDAQ:NAMS) Beats Q1 Revenue and EPS Estimates as Key Trial Catalysts Loom

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma Q1 EPS $(0.40) Beats $(0.47) Estimate, Sales $3.040M Beat $936.364K Estimate

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today

A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib’s Phase 3 LDL C Results

NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Upcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS)

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

This Biotech Was Quietly Bought Before a $58 Per Share Takeout

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share Offering

Guggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45